Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.50 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 6/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5045179 | 1.00 | KMT2A (0.55) | KMT2AMEN1ATMALDH1A1PDCD1 | |
| SCHEMBL5045185 | 1.00 | KMT2A (0.55) | KMT2AMEN1ATMALDH1A1PDCD1 | |
| SCHEMBL1976999 | 0.91 | KMT2A (0.61) | KMT2AMEN1ATMALDH1A1PDCD1 | |
| SCHEMBL1126098 | 0.82 | ALDH1A1 (0.47) | KMT2AMEN1ALDH1A1PDCD1CD274 | |
| SCHEMBL20255702 | 0.82 | ALDH1A1 (0.47) | KMT2AMEN1ALDH1A1PDCD1CD274 | |
| SCHEMBL1126096 | 0.82 | ALDH1A1 (0.47) | KMT2AMEN1ALDH1A1PDCD1CD274 | |
| SCHEMBL2234417 | 0.82 | ALDH1A1 (0.47) | KMT2AMEN1ALDH1A1PDCD1CD274 | |
| SCHEMBL20255353 | 0.82 | ALDH1A1 (0.47) | KMT2AMEN1ALDH1A1PDCD1CD274 | |
| SCHEMBL1126239 | 0.82 | ALDH1A1 (0.47) | KMT2AMEN1ALDH1A1PDCD1CD274 | |
| SCHEMBL31093335 | 0.80 | KMT2A (0.59) | KMT2AMEN1ATMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7345038-B2 | Pyridyloxymethyl and benzisoxazole azabicyclic derivatives | PFIZER, INC (US) | 2008-03-18 | — | — | US | disclosed |
| EP-1608648-A1 | PYRIDYLOXYMETHYL AND BENZISOXAZOLE AZABICYCLIC DERIVATIVES | Pfizer Products Inc. (US) | 2005-12-28 | — | — | EP | disclosed |
| US-20050026922-A1 | For treating CNS or other disorders, including concurrent treatment of disorders such as schizophrenia and depression; side effect reduction; for example, (7R,9aS)-trans-7-[6-(2,6-Dimethyl-piperidin-1-ylmethyl)-pyridin-2-yloxymethyl]-2-(5-fluoro-benzo[d]isoxazol-3-yl)-octahydro-pyrido[1,2-a]pyrazine | PFIZER INC | 2005-02-03 | — | — | US | disclosed |
| WO-2004081007-A1 | PYRIDYLOXYMETHYL AND BENZISOXAZOLE AZABICYCLIC DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026922-A1 | For treating CNS or other disorders, including concurrent treatment of disorders such as schizophrenia and depression; side effect reduction; for example, (7R,9aS)-trans-7-[6-(2,6-Dimethyl-piperidin-1-ylmethyl)-pyridin-2-yloxymethyl]-2-(5-fluoro-benzo[d]isoxazol-3-yl)-octahydro-pyrido[1,2-a]pyrazine | GRM7, GRIN2C, HTR7 | KMT2A 1126/4885MEN1 4086/4885ATM 4703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.